Literature DB >> 33512659

Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.

Fengyang Li1, Dan Xu1, Kai Hou2, Xue Gou1, Ning Lv1, Weirong Fang3, Yunman Li4.   

Abstract

Increasing studies showed that several anti-platelet drugs turned out to be a promising strategy for inflammatory response. In this study, we investigated the protective efficiency of pretreatment of indobufen or aspirin combined with clopidogrel or ticagrelor (IACT) on cerebral ischemic injury via NF-κB/NLRP3 pathway. Ischemia/reperfusion (I/R) injury was simulated in vivo by middle cerebral artery occlusion/reperfusion (MCAO/R) model, and rats were pretreated with indobufen and aspirin and their combinations with clopidogrel or ticagrelor respectively. The platelet aggregation, cerebral infarct size, water content, neurological impairment and LDH release were measured. The relative expression of inflammasome mediated pyroptosis was determined by ELISA, RT-PCR, Tunel, Immunofluorescence and Western blotting as appropriate. In vitro, I/R injury was simulated in PC12 cells using oxygen glucose deprivation/reperfusion (OGD/R) and Lipopolysaccharide (LPS) to induce pyroptosis. The effect of combinations were significantly greater than MCAO/R group on decreasing the platelet aggregation, infarct size, brain edema, LDH release and neurologic impairment. LPS aggravated I/R-induced PC12 cell injury, which was significantly suppressed by pretreatment of IACT and Bay11-7082. Mechanistically, IACT alleviated transcriptionally encoded IL-1β, IL-18 and NLRP3 via inhibiting nuclear transportation of NF-κB. Importantly, at protein level, NLRP3, Caspase-1, IL-18, IL-1β and GSDMD were significantly decreased in combination groups both in vivo and vitro. IACT reduce inflammasome mediated pyroptosis in MCAO/R rats and OGD/R PC12 cells through inhibiting NF-κB/NLRP3 signaling pathway, which suggests that drug combination is a protective strategy with clinical potential against I/R-induced injury. Graphical abstract.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Drug combinations; Inflammatory; Ischemia/reperfusion injury; Ischemic stroke; NF-κB/NLRP3 pathway; Pyroptosis

Mesh:

Substances:

Year:  2021        PMID: 33512659     DOI: 10.1007/s11481-020-09978-9

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  54 in total

1.  Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.

Authors:  O Belton; D Byrne; D Kearney; A Leahy; D J Fitzgerald
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

Review 2.  Inflammasomes: mechanism of action, role in disease, and therapeutics.

Authors:  Haitao Guo; Justin B Callaway; Jenny P-Y Ting
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

3.  A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study.

Authors:  B Bergamasco; P Benna; A Carolei; M Rasura; G Rudelli; C Fieschi
Journal:  Funct Neurol       Date:  1997 Jan-Feb

4.  [Chronic treatment of vascular diseases with indobufen].

Authors:  G Belcaro; B M Errichi; G Laurora; R Marinucci; M R Cesarone; A De Cenzo
Journal:  Minerva Cardioangiol       Date:  1989-05       Impact factor: 1.347

5.  Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study.

Authors:  G Fornaro; P Rossi; P G Mantica; M E Caccia; D Aralda; M Lavezzari; F Pamparana; G Milanesi
Journal:  Circulation       Date:  1993-01       Impact factor: 29.690

6.  Clematichinenoside protects blood brain barrier against ischemic stroke superimposed on systemic inflammatory challenges through up-regulating A20.

Authors:  Dan Han; Weirong Fang; Rui Zhang; Jie Wei; Nandani Darshika Kodithuwakku; Lan Sha; Wenhuan Ma; Lifang Liu; Fengwen Li; Yunman Li
Journal:  Brain Behav Immun       Date:  2015-07-29       Impact factor: 7.217

7.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.

Authors:  J B Bederson; L H Pitts; M Tsuji; M C Nishimura; R L Davis; H Bartkowski
Journal:  Stroke       Date:  1986 May-Jun       Impact factor: 7.914

Review 8.  Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1).

Authors:  G Fantuzzi; C A Dinarello
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.542

9.  Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke.

Authors:  D Yang-Wei Fann; S Y Lee; S Manzanero; S C Tang; M Gelderblom; P Chunduri; C Bernreuther; M Glatzel; Y L Cheng; J Thundyil; A Widiapradja; K Z Lok; S L Foo; Y C Wang; Y I Li; G R Drummond; M Basta; T Magnus; D G Jo; M P Mattson; C G Sobey; T V Arumugam
Journal:  Cell Death Dis       Date:  2013-09-05       Impact factor: 8.469

10.  Serum amyloid A primes microglia for ATP-dependent interleukin-1β release.

Authors:  Laura Facci; Massimo Barbierato; Morena Zusso; Stephen D Skaper; Pietro Giusti
Journal:  J Neuroinflammation       Date:  2018-05-26       Impact factor: 8.322

View more
  7 in total

1.  lncRNA GAS5 promotes pyroptosis in COPD by functioning as a ceRNA to regulate the miR‑223‑3p/NLRP3 axis.

Authors:  Rubing Mo; Jing Li; Yongxing Chen; Yipeng Ding
Journal:  Mol Med Rep       Date:  2022-05-18       Impact factor: 3.423

Review 2.  NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia-Reperfusion Injury.

Authors:  Lixia Wang; Wei Ren; Qingjuan Wu; Tianzhu Liu; Ying Wei; Jiru Ding; Chen Zhou; Houping Xu; Sijin Yang
Journal:  Front Mol Neurosci       Date:  2022-05-06       Impact factor: 6.261

3.  Neuroprotective Effects of Salicin in a Gerbil Model of Transient Forebrain Ischemia by Attenuating Oxidative Stress and Activating PI3K/Akt/GSK3β Pathway.

Authors:  Joon-Ha Park; Tae-Kyeong Lee; Dae-Won Kim; Hyejin Sim; Jae-Chul Lee; Jong-Dai Kim; Ji-Hyeon Ahn; Choong-Hyun Lee; Young-Myeong Kim; Moo-Ho Won; Soo-Young Choi
Journal:  Antioxidants (Basel)       Date:  2021-04-20

4.  Protective Effects of Remimazolam on Cerebral Ischemia/Reperfusion Injury in Rats by Inhibiting of NLRP3 Inflammasome-Dependent Pyroptosis.

Authors:  Min Shi; Jing Chen; Tianxiao Liu; Weixin Dai; Zhan Zhou; Lifei Chen; Yubo Xie
Journal:  Drug Des Devel Ther       Date:  2022-02-18       Impact factor: 4.162

5.  Do pyroptosis, apoptosis, and necroptosis (PANoptosis) exist in cerebral ischemia? Evidence from cell and rodent studies.

Authors:  Wei-Tao Yan; Yan-Di Yang; Xi-Min Hu; Wen-Ya Ning; Lyu-Shuang Liao; Shuang Lu; Wen-Juan Zhao; Qi Zhang; Kun Xiong
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

6.  Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study.

Authors:  Qiu-Ping Shi; Xing-Yu Luo; Bin Zhang; Xin-Gang Wang; Jing Zhao; Qiu-Fen Xie; Jia-Hui Liu; Yao-Kun Liu; Jie Jiang; Bo Zheng
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 7.  NLRP3 inflammasome: The rising star in cardiovascular diseases.

Authors:  Yidan Zheng; Li Xu; Nianguo Dong; Fei Li
Journal:  Front Cardiovasc Med       Date:  2022-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.